News
VTVT
21.28
+17.12%
3.11
12 Health Care Stocks Moving In Wednesday's Intraday Session
Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. VTv Therapeutics stock increased by 43.09% to $26.0. Avidity Biosciences shares increased by 32.32% during the session. ThermoGenesis Holdings shares fell 31.4% in the same session.
Benzinga · 6h ago
Weekly Report: what happened at VTVT last week (0603-0607)?
Weekly Report · 2d ago
Weekly Report: what happened at VTVT last week (0527-0531)?
Weekly Report · 06/03 12:15
Goldman Sachs raises obesity drug market estimate to $130B
Goldman Sachs raises obesity drug market estimate to $130B in 2030. Number of Americans on anti-obesity drugs could reach 19M by 2030. GLP-1 receptor agonists will dominate the next-gen weight loss drug market. Novo Nordisk (NVO) and Eli Lilly traded higher on Thursday.
Seeking Alpha · 05/30 15:22
Weekly Report: what happened at VTVT last week (0520-0524)?
Weekly Report · 05/27 12:22
Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By vtv Therapeutics, Which Cantex Licensed Worldwide Rights
FDA grants Orphan Drug Designation to Cantex Pharmaceuticals' azeliragon for the treatment of pancreatic cancer. Cantex is a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening conditions. The company's pill is well-tolerated once-a-day.
Benzinga · 05/20 16:04
Weekly Report: what happened at VTVT last week (0513-0517)?
Weekly Report · 05/20 12:11
Weekly Report: what happened at VTVT last week (0506-0510)?
Weekly Report · 05/13 12:30
vTv Therapeutics Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/10 15:56
VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024
VTv Therapeutics just reported results for the first quarter of 2024. The company reported earnings per share of -$1.17 and revenue of $1.00 million. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports.
Investorplace · 05/10 02:57
vTv Therapeutics Q1 EPS $(1.17) Up From $(2.40) YoY, Sales $1.00M
Benzinga · 05/09 22:08
vTv Therapeutics GAAP EPS of -$1.17, revenue of $1M
Seeking Alpha · 05/09 21:37
VTV THERAPEUTICS INC - NET LOSS ATTRIBUTABLE TO VTV SHAREHOLDERS FOR THREE MONTHS ENDED MARCH 31, 2024, WAS $4.9 MLN OR $1.17 PER BASIC SHARE
Reuters · 05/09 20:51
VTV THERAPEUTICS Q1 OPERATING EXPENSES USD 6.627 MILLION
Reuters · 05/09 20:51
*vTv Therapeutics 1Q Loss/Shr $1.17 >VTVT
Dow Jones · 05/09 20:51
*VTv Therapeutics 1Q Rev $1M >VTVT
Dow Jones · 05/09 20:51
Press Release: vTv Therapeutics Announces 2024 -2-
VTv Therapeutics Inc. Is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. This release contains forward-looking statements that involve risks and uncertainties. VTv has a pipeline of clinical drug candidates for the treatment of type 1 diabetes.
Dow Jones · 05/09 20:51
VTV THERAPEUTICS INC - QTRLY REVENUE $1 MLN
Reuters · 05/09 20:30
VTV THERAPEUTICS INC - QTRLY NET LOSS ATTRIBUTABLE $1.17 PER BASIC SHARE
Reuters · 05/09 20:30
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.